Key Highlights:
- AT278 insulin data published in a peer-reviewed Journal in August 2026
- Positive FDA Type C meeting feedback received on Phase 2 trial design
- FY25 profit of £0.664m driven by a one-off gain from a Royalty sale to Ligand
- Cash and investments of £6.130m, with a going-concern runway to May 2027
- Co-development Partnership with Sequel Med Tech for insulin pump integration
Arecor Therapeutics PLC (LSE:AREC) has spent 2026 turning a drug-delivery technology Business into a focused diabetes and obesity play, and the next six months will show whether that bet pays off. The Cambridge-based biotech aims to take AT278, an ultra-concentrated, ultra-rapid-acting insulin, into Phase 2 in the second half of 2026 alongside US pump maker Sequel Med Tech, and a peer-reviewed publication on 13 August 2026 gave the programme fresh validation.
The question is timing. Arecor reported an annual profit for 2025, but only thanks to a one-off gain from selling royalty rights to Ligand Pharmaceuticals, and its accounts carry a material uncertainty over Going Concern with a base-case cash runway to May 2027. An AT278 partnering deal and the terms of the next funding round will decide how much pipeline value accrues to existing shareholders.
Peer-reviewed AT278 data lands ahead of Phase 2
Arecor’s most recent material announcement came on 13 August 2026, when it reported that its AT278-104 study had been published in Diabetes, Obesity and Metabolism. The trial compared AT278, a 500 units per millilitre insulin aspart, against standard U100 insulin aspart and U500 human regular insulin in people with type 2 diabetes needing high daily doses.
AT278 was absorbed significantly faster than both comparators, produced a greater glucose-lowering effect in the first hour, and kept its ultra-rapid profile regardless of body mass index, with a favourable safety profile. Chief scientific officer Dr Jan Jezek said the publication “provides peer-reviewed validation of our work advancing next-generation insulin formulations for high-dose requirements”, adding that AT278 could become “the first ultra-rapid U500 insulin for prandial use”.
The publication strengthens the data package Arecor is using to court partners. In its 13 April 2026 final results, the company said it had received positive FDA Type C meeting feedback on its Phase 2 design, planned an Investigational New Drug filing in 2026, and had confirmed with Sequel Med Tech a strategic intent to enter a broader co-development and commercialisation partnership. On 26 March 2026, Arecor also received a $0.5m milestone from Ligand Pharmaceuticals under its September 2025 royalty financing.
Arecor is a clinical-stage biopharmaceutical company built around Arestat, a proprietary formulation technology that improves the stability, concentration and delivery of proteins and peptides. Since closing its Tetris Pharma commercial Subsidiary in 2025 and returning Ogluo rights to Xeris BioPharma, it has focused on diabetes and oral peptide delivery.
The lead asset is AT278, designed for automated insulin delivery systems. Arecor argues that patients needing more than 100 units a day cannot achieve standard three-day pump wear with existing U100 insulins, and estimates an initial US addressable market of over $3bn a year across roughly two million patients. In September 2025 it signed a co-development deal with Sequel Med Tech, maker of the twiist insulin pump, with a combined $2.6m commitment for Phase 2-enabling work. A second programme applies Arestat to oral GLP-1 receptor agonists such as semaglutide, with a European Patent application filed and non-clinical pharmacokinetic studies planned for 2026.
Arecor also earns Revenue from formulation collaborations with pharmaceutical partners, three of which were signed in 2025, and holds more than 100 granted patents.
FY25 results: profit on paper, cash from royalty sale
For the year to 31 December 2025, Arecor reported continuing revenue of £1.714m, up marginally from £1.643m. Other Operating Income jumped to £5.534m from £0.267m, almost all of it a £4.968m gain on the sale of intangible assets to Ligand, which paid $7.0m (£5.2m) upfront for global royalty rights to AT220 and milestone rights linked to AT292, licensed to Sanofi.
R&D spending fell to £2.694m from £3.041m. Continuing operations delivered an operating profit of £0.932m, against a £5.176m loss, and a profit before tax of £0.994m compared with a £5.093m loss. Including a £0.268m loss from the discontinued Tetris business, total group profit was £0.664m versus a £10.236m loss, giving Earnings Per Share of 2 pence against a 31 pence loss. Without the one-off gain, the business remained loss-making.
Year-end cash was £3.001m, plus £3.129m in short-term investments, for total cash and investments of £6.130m, up from £3.257m. The directors said their base case supports operations until May 2027, with a downside case to April 2027, and that additional funding is required by the second quarter of 2027. The accounts flag a material uncertainty over going concern, though the board considers the basis appropriate given its record of raising money through equity, partnering and royalty deals. No Dividend is paid.
The most obvious catalyst is a definitive AT278 partnership. Chief executive Sarah Howell said the board’s priority is securing “the best possible deal to take AT278 into Phase 2 in 2H 2026”, and any agreement bringing upfront cash or cost-sharing would address the funding overhang. An IND filing and trial start would follow.
Half-year figures should also be imminent: Arecor (LSE:AREC) published its 2025 interims on 25 September 2025, so H1 2026 numbers would ordinarily follow in September. The second $0.5m Ligand milestone is expected in the second half of 2026, with up to $3m more contingent on commercial milestones for AT220 and AT292. Initial pharmacokinetic data from the oral GLP-1 programme would give the market a second story to price, and new formulation collaborations remain a steady source of newsflow.
Funding is the central risk. With a Market Capitalisation of about £27.9m at 74p on 2 September 2026, according to market data, and cash needed by the second quarter of 2027, any Equity raise would be significant relative to the company’s size and potentially dilutive.
Partnering risk follows closely: if the Sequel Med Tech relationship does not convert into a fully funded deal, Arecor may have to finance more of Phase 2 itself. Phase 1 data are encouraging, but Phase 2 in a real-world pump setting is a larger test, and regulatory timelines can slip. Continuing revenue is small at £1.7m and lumpy, and royalty upside from AT220 and AT292 is now capped at the Ligand milestones. The shares are thinly traded, with a 52-week range of 55.8p to 92.5p.
Arecor enters the autumn with a sharper focus, a lead asset backed by peer-reviewed data and FDA feedback, and a stated route into Phase 2. What it lacks is the funding to see that trial through, as the FY25 going-concern language makes explicit. Investors should watch the H1 2026 results and cash balance, the terms of any AT278 partnership, an IND filing and trial start, and early oral GLP-1 data. Those will determine whether 2026 marks a genuine turning point for AREC or another year of promise awaiting capital.






Please wait processing your request...